Filgrastim biosimilar (Fresenius Kabi Oncology)

非格司亭生物类似药（Fresenius Kabi Oncology）

Report date: 2022/02/11 17:32:53

Base Information

Drug NameFilgrastim biosimilar (Fresenius Kabi Oncology)

Drug Alias NameRecombinant human granulocyte macrophage colony stimulating factor (Fresenius Kabi Oncology)非格司亭生物仿制药（Fresenius Kabi Oncology）重组人粒细胞刺激因子（Fresenius Kabi Oncology）rhG-CSF (Fresenius Kabi Oncology)

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines

Mechanisms of ActionColony stimulating factor 3 receptor agonists

TargetsColony stimulating factor 3 receptor

Therapy Area/IndicationsNeutropenia

Global Approved IndicationsNeutropenia

Approved Indications in ChinaN/A

Original Approved Country/TerritoryIndia

Original Approved Date2012/08/01

Country/TerritoryIndia

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesFresenius Kabi Ag

China Registration ClassN/A

Develop Information

Active CompaniesFresenius Kabi Ag

Inactive CompaniesN/A

Active IndicationsNeutropenia

Inactive IndicationsN/A

Other Information

ATC CodeL03AA02